David B. Lovejoy

3.2k total citations
25 papers, 2.9k citations indexed

About

David B. Lovejoy is a scholar working on Oncology, Inorganic Chemistry and Nutrition and Dietetics. According to data from OpenAlex, David B. Lovejoy has authored 25 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 11 papers in Inorganic Chemistry and 9 papers in Nutrition and Dietetics. Recurrent topics in David B. Lovejoy's work include Metal complexes synthesis and properties (21 papers), Drug Transport and Resistance Mechanisms (11 papers) and Trace Elements in Health (9 papers). David B. Lovejoy is often cited by papers focused on Metal complexes synthesis and properties (21 papers), Drug Transport and Resistance Mechanisms (11 papers) and Trace Elements in Health (9 papers). David B. Lovejoy collaborates with scholars based in Australia, United States and United Kingdom. David B. Lovejoy's co-authors include Des R. Richardson, Danuta S. Kalinowski, Paul V. Bernhardt, Philip C. Sharpe, Jun Yuan, Yu Yu, Mohammad Shahidul Islam, Patric J. Jansson, Ralph Watts and Christian Stefani and has published in prestigious journals such as Blood, Clinical Cancer Research and Journal of Medicinal Chemistry.

In The Last Decade

David B. Lovejoy

25 papers receiving 2.9k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David B. Lovejoy Australia	18	1.7k	1.0k	938	524	492	25	2.9k
Philip C. Sharpe Australia	24	1.7k 1.0×	1.0k 1.0×	811 0.9×	631 1.2×	342 0.7×	40	2.8k
Patric J. Jansson Australia	42	2.4k 1.4×	981 0.9×	2.6k 2.8×	417 0.8×	834 1.7×	85	5.5k
Dick Pluim Netherlands	29	2.8k 1.7×	899 0.9×	1.6k 1.7×	159 0.3×	166 0.3×	70	4.2k
James D. Hoeschele United States	27	1.9k 1.1×	1.3k 1.2×	833 0.9×	443 0.8×	148 0.3×	65	2.9k
Michael Frezza United States	14	1.0k 0.6×	640 0.6×	847 0.9×	192 0.4×	102 0.2×	15	1.9k
Christian R. Kowol Austria	37	3.1k 1.9×	2.2k 2.1×	1.3k 1.4×	839 1.6×	333 0.7×	109	4.8k
Kenneth R. Harrap United Kingdom	33	2.3k 1.4×	963 0.9×	1.9k 2.0×	105 0.2×	149 0.3×	108	4.3k
Qiuzhi Cindy Cui United States	20	863 0.5×	431 0.4×	1.4k 1.5×	115 0.2×	290 0.6×	27	2.8k
David E. Heppner United States	26	933 0.6×	611 0.6×	1.4k 1.4×	1.1k 2.0×	144 0.3×	50	3.3k
Virginia H. Mansour United States	9	2.5k 1.5×	1.8k 1.7×	1.1k 1.2×	373 0.7×	97 0.2×	13	3.5k

Countries citing papers authored by David B. Lovejoy

Since Specialization

Citations

This map shows the geographic impact of David B. Lovejoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David B. Lovejoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David B. Lovejoy more than expected).

Fields of papers citing papers by David B. Lovejoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David B. Lovejoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David B. Lovejoy. The network helps show where David B. Lovejoy may publish in the future.

Co-authorship network of co-authors of David B. Lovejoy

This figure shows the co-authorship network connecting the top 25 collaborators of David B. Lovejoy. A scholar is included among the top collaborators of David B. Lovejoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David B. Lovejoy. David B. Lovejoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kurantsin‐Mills, Joseph, John Kwagyan, Danuta S. Kalinowski, et al.. (2013). Anti-plasmodial activity of aroylhydrazone and thiosemicarbazone iron chelators: Effect on erythrocyte membrane integrity, parasite development and the intracellular labile iron pool. Journal of Inorganic Biochemistry. 129. 43–51. 30 indexed citations

Debebe, Zufan, Sergeï Nekhai, David B. Lovejoy, et al.. (2012). Development of a sensitive HPLC method to measure in vitro permeability of E- and Z-isomeric forms of thiosemicarbazones in Caco-2 monolayers. Journal of Chromatography B. 906. 25–32. 15 indexed citations

Lui, Goldie Y.L., Peyman Obeidy, Samuel Ford, et al.. (2012). The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against Human Lung Tumor Xenografts and Molecular Mechanism of Action. Molecular Pharmacology. 83(1). 179–190. 115 indexed citations

Lovejoy, David B., Danae M. Sharp, Nicole A. Seebacher, et al.. (2012). Novel Second-Generation Di-2-Pyridylketone Thiosemicarbazones Show Synergism with Standard Chemotherapeutics and Demonstrate Potent Activity against Lung Cancer Xenografts after Oral and Intravenous Administration in Vivo. Journal of Medicinal Chemistry. 55(16). 7230–7244. 179 indexed citations

Kovačević, Žaklina, Danuta S. Kalinowski, David B. Lovejoy, et al.. (2011). The Medicinal Chemistry of Novel Iron Chelators for the Treatment of Cancer. Current Topics in Medicinal Chemistry. 11(5). 483–499. 67 indexed citations

Merlot, Angelica M., Namfon Pantarat, David B. Lovejoy, Danuta S. Kalinowski, & Des R. Richardson. (2010). Membrane Transport and Intracellular Sequestration of Novel Thiosemicarbazone Chelators for the Treatment of Cancer. Molecular Pharmacology. 78(4). 675–684. 19 indexed citations

Yu, Yu, Danuta S. Kalinowski, Žaklina Kovačević, et al.. (2009). ChemInform Abstract: Thiosemicarbazones from the Old to New: Iron Chelators that Are More than Just Ribonucleotide Reductase Inhibitors. ChemInform. 40(50). 7 indexed citations

Kovařı́ková, Petra, et al.. (2008). HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents. Journal of Chromatography B. 877(3). 316–322. 18 indexed citations

Bernhardt, Paul V., Philip C. Sharpe, Mohammad S. Islam, et al.. (2008). Iron Chelators of the Dipyridylketone Thiosemicarbazone Class: Precomplexation and Transmetalation Effects on Anticancer Activity. Journal of Medicinal Chemistry. 52(2). 407–415. 151 indexed citations

10.

Kalinowski, Danuta S., Yu Yu, Philip C. Sharpe, et al.. (2007). Design, Synthesis, and Characterization of Novel Iron Chelators: Structure−Activity Relationships of the 2-Benzoylpyridine Thiosemicarbazone Series and Their 3-Nitrobenzoyl Analogues as Potent Antitumor Agents. Journal of Medicinal Chemistry. 50(15). 3716–3729. 205 indexed citations

11.

Yu, Yu, Jacky Wong, David B. Lovejoy, Danuta S. Kalinowski, & Des R. Richardson. (2006). Chelators at the Cancer Coalface: Desferrioxamine to Triapine and Beyond. Clinical Cancer Research. 12(23). 6876–6883. 170 indexed citations

12.

Chaston, Timothy B., David B. Lovejoy, Ralph Watts, & Des R. Richardson. (2003). Examination of the antiproliferative activity of iron chelators: multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311.. PubMed. 9(1). 402–14. 179 indexed citations

13.

Bernhardt, Paul V., et al.. (2003). Four cytotoxic N4-substituted thiosemicarbazones derived from 2-hydroxynaphthalene-1-carboxaldehyde. Acta Crystallographica Section C Crystal Structure Communications. 59(11). o629–o633. 9 indexed citations

14.

Becker, E., David B. Lovejoy, Judith M. Greer, Ralph Watts, & Des R. Richardson. (2003). Identification of the di‐pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti‐tumour agents. British Journal of Pharmacology. 138(5). 819–830. 95 indexed citations

15.

Loyevsky, Mark, et al.. (2003). Novel aroylhydrazone and thiosemicarbazone iron chelators with anti-malarial activity against chloroquine-resistant and -sensitive parasites. The International Journal of Biochemistry & Cell Biology. 36(3). 401–407. 187 indexed citations

16.

Lovejoy, David B. & Des R. Richardson. (2002). Novel “hybrid” iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood. 100(2). 666–676. 155 indexed citations

17.

Lovejoy, David B. & Des R. Richardson. (2000). Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Expert Opinion on Investigational Drugs. 9(6). 1257–1270. 16 indexed citations

18.

Lovejoy, David B., Des R. Richardson, & Paul V. Bernhardt. (2000). 2-Hydroxy-1-naphthaldehyde 2-methylthiosemicarbazone. Acta Crystallographica Section C Crystal Structure Communications. 56(3). 341–342. 5 indexed citations

19.

20.

Lovejoy, David B., Peter Leverett, Peter A. Williams, & Robert S. Vagg. (1999). CHIRAL METAL COMPLEXES. PART 52. THE STRUCTURES OF CO-CRYSTALLISED DIASTEREOISOMERIC DNA PROBES SHOWING INTRAMOLECULAR π-π INTERACTIONS. Journal of Coordination Chemistry. 49(2). 101–112. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact